A5078694527- Respiratory viral infections research
- Neonatal Respiratory Health Research
- Congenital Diaphragmatic Hernia Studies
- Dementia and Cognitive Impairment Research
- Pneumonia and Respiratory Infections
- Tracheal and airway disorders
- Attention Deficit Hyperactivity Disorder
- Adolescent and Pediatric Healthcare
- Alzheimer's disease research and treatments
- Child and Adolescent Health
- Health Systems, Economic Evaluations, Quality of Life
- Schizophrenia research and treatment
- Cancer Immunotherapy and Biomarkers
- Neuroethics, Human Enhancement, Biomedical Innovations
- Stroke Rehabilitation and Recovery
- Cystic Fibrosis Research Advances
- Cannabis and Cannabinoid Research
- Animal testing and alternatives
- Microscopic Colitis
- Congenital Heart Disease Studies
- Homelessness and Social Issues
- Treatment of Major Depression
- Infant Development and Preterm Care
- Alcoholism and Thiamine Deficiency
- Ginseng Biological Effects and Applications
Sunnybrook Hospital
2012-2023
Sunnybrook Research Institute
2012-2023
Sunnybrook Health Science Centre
2012-2021
Health Sciences Centre
2012-2021
University of Toronto
1998-2020
AbbVie (United States)
2016
Ospedale Sant'Anna
2016
McMaster University
2016
University of Calgary
2016
University of Turin
2016
Apathy is common in neurocognitive disorders (NCD) but NCD-specific diagnostic criteria are needed.The International Society for CNS Clinical Trials Methodology Work Group convened an expert group and sought input from academia, health-care, industry, regulatory bodies. A modified Delphi methodology was followed, included extensive literature review, two surveys, meetings at international conferences, culminating a consensus meeting 2019.The final reached with more than 80% agreement on all...
This is the report of first workshop on Incorporating In Vitro Alternative Methods for Developmental Neurotoxicity (DNT) Testing into International Hazard and Risk Assessment Strategies, held in Ispra, Italy, 19-21 April 2005. The was hosted by European Centre Validation (ECVAM) jointly organized ECVAM, Chemical Industry Council, Johns Hopkins University Center Alternatives to Animal Testing. primary aim identify catalog potential methods that could be used assess how data from vitro...
<h3>Importance</h3> Apathy, characterized by diminished will or initiative and one of the most prevalent neuropsychiatric symptoms in individuals with Alzheimer disease, is associated significant caregiver burden, excess disability, increased medical costs, mortality. <h3>Objective</h3> To measure whether methylphenidate compared placebo decreases severity apathy disease. <h3>Design, Setting, participants</h3> This multicenter randomized placebo-controlled clinical trial was conducted from...
Abstract Low‐rate dynamic contact angles of 13 liquids on a polystyrene polymer are measured by an automated axisymmetric drop shape analysis – profile (ADSA‐P). It is found that 7 yielded non‐constant angles, and/or dissolved the contact. From experimental other 6 liquids, it liquid‐vapor surface tension times cosine angle changes smoothly with tension, i.e. γ lv cosθ depends only for given solid (or tension). This pattern in harmony those from inert and non‐inert (polar non‐polar) surfaces...
Background: Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children. However, relatively little known about the current use, compliance, and outcomes associated with this medication. Methods: A prospective, observational, registry based on 27 sites, monthly follow-up of infants at high risk RSV who received least 1 dose palivizumab during 2005–2009 seasons. Results: total 5286 children were enrolled (56.6% male; 71.7% white; average gestational age,...
Children with Down syndrome (DS) are at significant risk for respiratory syncytial virus (RSV) infection and related hospitalization. We compared hospitalization rates due to tract in children DS aged <2 years who prospectively received palivizumab during the RSV season a previously published, similar untreated birth cohort.A total of 532 were assembled from prospective Canadian Evaluation Study Palivizumab registry between 2005 2012. The group included 233 derived nationwide Dutch cohort...
Palivizumab utilization, compliance, and outcomes were examined in infants with preexisting medical diseases within the Canadian Registry Database (CARESS) to aid developing guidelines for potential "at-risk" future. Infants who received ≥1 dose of palivizumab during 2006-2010 respiratory syncytial virus (RSV) seasons at 29 sites recruited related infection/illness (RI) events collected monthly. Hazard ratios (HRs) 95% confidence intervals (CIs) calculated premature ≤35 completed weeks...
Respiratory syncytial virus (RSV) infection occurs commonly in infants aged ≤2 years, and severe results hospitalization with accompanying morbidity mortality. Palivizumab has been available for prophylaxis the past 15 years. Prospective data on patients who received palivizumab from 2005 to 2012 assembled Canadian registry (CARESS) document utilization, compliance, health outcomes both hospital community settings. Long-term is necessary evaluate impact of incidence RSV infections, minimize...
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants. Palivizumab, means passive prophylaxis, relies on patient adherence to ensure therapeutic effectiveness. The objective this study evaluate the association between and incidence RSV-associated outcomes identify demographic factors that may impact adherence.Infants were recruited into Canadian registry palivizumab (CARESS) with parental consent. Monthly interviews collected information...
Background: Respiratory syncytial virus (RSV) infection frequently results in RSV-related hospitalization (RSVH) young infants. We examined the outcomes of palivizumab recipients within Canadian Registry (CARESS) and Torino-Verona Italian over 2002–2014 RSV seasons. Methods: RSVHs were captured during study Premature infants who received (≤35 completed weeks’ gestational age; group1) compared with given for underlying disorders regardless age (group 2). Variables between-group incidences...
We examined the dosing regimens, compliance, and outcomes of premature infants who received palivizumab within Canadian Registry Palivizumab (CARESS). Infants receiving ≥1 dose during 2006-2011 respiratory syncytial virus (RSV) seasons were recruited across 30 sites. Respiratory illness events captured monthly. ≤32 completed weeks gestational age (GA) (Group 1) compared to 33-35 GA 2) following prophylaxis. In total, 6,654 patients analyzed 1, n = 5,183; Group 2, 1,471). The mean was 29.9 ±...
Down syndrome (DS) is a risk factor for respiratory syncytial virus (RSV) hospitalization, but little known about prophylaxis in these children.CARESS prospective registry of children who received ≥1 dose palivizumab during the 2006-2012 RSV seasons across 32 sites Canada. The objective was to compare illness hospitalization and (RSVH) hazard ratios DS aged <2 years versus standard indications (SI) other medical illnesses (MI).13,310 were enrolled; (600; 4.5%), SI (11,081; 83.3%) MI (1629,...
ABSTRACT Background: Cholinesterase inhibitors (ChEIs) are being used for increasingly long periods of time, even in patients with severe Alzheimer's disease. Because there is little data to help clinicians decide on when it safe and appropriate discontinue ChEIs after long-term use, practices may vary widely. Methods: An internet-based survey was undertaken Canadian dementia experts (geriatric psychiatrists, neurologists, geriatricians) involved clinical trial research. Recommendations ChEI...
Objectives To evaluate the safety and tolerability of palivizumab for RSV prophylaxis in high-risk children everyday practice. Methods High-risk prophylaxed against infection were recruited into a prospective, observational, Canadian Evaluation Study Palivizumab (CARESS) registry with active, serious adverse event (SAE) monitoring from 2008 to 2013. SAE reports systematically collected assessed severity relationship palivizumab. Data analyzed by Chi-square or Fisher Exact Tests examine group...
Children aged <2 years with chronic lung disease (CLD) have a 10-fold higher risk for respiratory syncytial virus-positive hospitalization (RSVH) compared to healthy term infants. Based on the updated position statements, we respiratory-related illness (RIH) and RSVH risks in CLD children who received palivizumab during first year (FY) versus second (SY) of life Canadian Registry Palivizumab (CARESS). Demographic data were collected at enrolment RIH events recorded monthly from 2005 2015....
Objective This study aimed to evaluate palivizumab (PVZ) use, trends in indications, and outcomes of respiratory illness hospitalizations (RIH) syncytial virus (RSVH). Study Design It involves a large, Canadian prospective (2005–2017) observational multicenter children at high risk for RSV infection. Results A total 25,003 infants (56.3% male) were enrolled 32 sites; 109,579 PVZ injections administered. Indications included: prematurity (63.3%); “miscellaneous” (17.8%); hemodynamically...
Objective: Vascular risk factors (VRFs) have been associated with stroke and cognitive impairment, however, the role of VRFs in predicting post-stroke depression (PSD) has not assessed. The objective current study was to determine whether are PSD an acute population. Methods: In this observational study, patients meeting World Health Organization MONICA Project National Institute Neurological Disorders Stroke criteria for were eligible. Patients assessed depression, cognition, severity, VRF...